Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

104.01 +2.22 (+2.18%)

Streaming Delayed Price Updated: 10:52 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 Next >

EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters ↗

June 29, 2021

The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial...

Via Benzinga

FDA AdCom In Favor Of Delaying Incyte's Retifanlimab Approval In Anal Cancer ↗

June 25, 2021

Members of the Oncologic Drugs Advisory Committee

Via Benzinga

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

June 25, 2021

From Incyte

Via Business Wire

Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

June 24, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗

June 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...

Via Benzinga

How This Pharma Company Can Benefit From Its Competitors ↗

June 20, 2021

Delays in FDA approval for Incyte could spell good news for Sanofi.

Via The Motley Fool

3 Promising Oncology Stocks To Consider Adding To Your Portfolio ↗

June 14, 2021

With tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca, Amgen and Incyte are worth adding to a portfolio.

Via Talk Markets

Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference

June 12, 2021

From Incyte

Via Business Wire

Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis

June 11, 2021

From Incyte Corporation

Via Business Wire

Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)

June 08, 2021

From Incyte

Via Business Wire

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

June 04, 2021

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a...

From MorphoSys AG

Via AccessWire

Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

June 04, 2021

From Incyte

Via Business Wire

Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial ↗

June 02, 2021

Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of...

Via Benzinga

Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover ↗

June 02, 2021

MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high.

Via Investor's Business Daily

BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients ↗

June 02, 2021

BriaCell Therapeutics Corp (NASDAQ: BCTX) has provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated advanced breast...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates ↗

June 01, 2021

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...

Via Benzinga

Week In Review: Nikang Raises $200 Million From US And China Investors ↗

May 29, 2021

NiKang Therapeutics, a clinical stage Delaware biotech, raised $200 million in a Series C financing from US and China investors. NiKang was originally incubated by CBC Group (C-Bridge Capital) in...

Via Talk Markets

Incyte to Present at Upcoming Investor Conferences

May 20, 2021

From Incyte

Via Business Wire

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting

May 19, 2021

From Incyte

Via Business Wire

Incyte's Ruxolitinib Cream Aces Late-Stage Vitiligo Trials, Teeing Up Regulatory Submissions ↗

May 17, 2021

Incyte Corporation (NASDAQ: INCY) has announced positive topline results from its pivotal Phase 3 TRuE-V trial program evaluating ruxolitinib cream in...

Via Benzinga

Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

May 17, 2021

From Incyte

Via Business Wire

The QQQ Was Hammered Again Today. Here's Why. ↗

May 12, 2021

U.S. indices were trading lower across the board Wednesday after CPI data showed an increase in U.S. inflation, which has weighed on stocks.

Via Benzinga

Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress

May 12, 2021

From Incyte

Via Business Wire

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

May 11, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗

May 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...

Via Benzinga

Incyte Corp (INCY) Q1 2021 Earnings Call Transcript ↗

May 04, 2021

INCY earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Incyte's Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance ↗

May 04, 2021

Incyte Corporation (NASDAQ: INCY) reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of...

Via Benzinga

The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗

May 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Recap: Incyte Q1 Earnings ↗

May 04, 2021

Shares of Incyte (NASDAQ:INCY) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 123.43% year over year to $0.67, which...

Via Benzinga

< Previous 1 2

...

19 20 21 22 23 24 25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.